Consensus Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
91.20 ^USD	-1.49%		-2.88%	-10.71%

Mar. 05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
Mar. 04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI

Evolution of the Average Target: Guardant Health, Inc.

Evolution of the Target Price: Guardant Health, Inc.

Changes in Analyst Recommendations: Guardant Health, Inc.

f536779449d133.Ta1N26EMDiaZE8uaGn3iz3nk2A8kDPwSCl_DxbdhKH8.NO8Pk5N9bX_PSaXtKAeWtkG-h3ljXYsqXh23_cYiEDwkyiqs_kA6QPBiuA~7e01ba4aec814b441e93a1c7d9344816

Analysts' recommendations: Guardant Health, Inc.

Feb. 17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
Jan. 30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
Dec. 02	Morgan Stanley Raises Price Target on Guardant Health to $130 From $105, Keeps Overweight Rating	MT
25-10-30	UBS Adjusts Guardant Health Price Target to $110 From $80, Maintains Buy Rating	MT
25-09-29	Guardant Health Says US FDA Approves its Blood Test as Companion Diagnostic for Eli Lilly's Inluriyo	MT
25-09-25	Guardant Health Shares Rise After Wolfe Upgrade	MT
25-09-25	UBS Adjusts Guardant Health Price Target to $80 From $70, Maintains Buy Rating	MT
25-09-25	Wolfe Research Upgrades Guardant Health to Outperform From Peer Perform, Price Target is $75	MT
25-07-30	Guardant Health Q2 revenue beats estimates	RE
25-05-02	Morgan Stanley Raises Price Target on Guardant Health to $60 From $52, Keeps Overweight Rating	MT
25-05-01	UBS Adjusts Guardant Health Price Target to $70 From $65, Maintains Buy Rating	MT
25-04-14	BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating	MT
25-04-10	Mizuho Initiates Guardant Health at Outperform	MT
25-03-06	Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says	MT
25-03-05	Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating	MT
25-02-21	UBS Adjusts Guardant Health Price Target to $65 From $40, Maintains Buy Rating	MT
25-01-23	Barclays Initiates Guardant Health at Overweight	MT
24-08-26	Nephron Research Downgrades Guardant Health to Sell From Hold, $23 Price Target	MT
24-08-21	UBS Raises Price Target on Guardant Health to $40 From $32, Maintains Buy Rating	MT
24-06-28	Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36	MT
24-06-04	Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating	MT
24-06-03	Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target	MT
24-04-29	Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating	MT
24-04-15	Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	MT
24-02-26	Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GUARDANT HEALTH, INC.					+45.36%
	BIOMÉRIEUX					+22.12%
	SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.					+28.96%
	CARIS LIFE SCIENCES, INC.					+80.74%
	LANTHEUS HOLDINGS, INC.					+25.41%
	DIASORIN S.P.A.					+15.85%
	AUTOBIO DIAGNOSTICS CO., LTD.					+27.09%
	10X GENOMICS, INC.					-3.21%
	Average					+30.29%
	Weighted average by Cap.					+33.17%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

91.20USD

Average target price

132.57USD

Spread / Average Target

+45.36%

High Price Target

180.00USD

Spread / Highest target

+97.37%

Low Price Target

90.00USD

Spread / Lowest Target

-1.32%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Baird
UBS
Morgan Stanley
Wolfe Research
BofA Securities
Mizuho Securities
Barclays
Canaccord Genuity
Jefferies & Co.
Goldman Sachs
Piper Sandler
Raymond James
Bernstein
Citigroup
Credit Suisse
Scotiabank
Cowen
BTIG
JPMorgan Chase
Stephens Inc.
Craig-Hallum
SVB Leerink
Stifel Nicolaus
Wells Fargo Securities